Inhaled Essential Oil Effect on Common QOL Concerns During Cancer Treatment
NCT ID: NCT03858855
Last Updated: 2020-08-04
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
248 participants
INTERVENTIONAL
2019-02-18
2020-04-13
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Aromatherapy and Essential Oils in Improving Insomnia and Other Symptoms in Patients With Newly Diagnosed Acute Leukemia Undergoing Chemotherapy
NCT02445378
Aromatherapy Essential Oils to Manage Anxiety and Nausea in Cancer Patients Receiving Infusion in the Ambulatory Setting
NCT07126301
Aromatherapy for Integrated Cancer Care
NCT03449511
Women With Breast Cancer Undergoing Chemotherapy: Implications in Quality of Life
NCT03585218
The Effects of Inhaled Aromatherapy on Chemotherapy Induced Nausea (CINV) and Vomiting
NCT04478630
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
I. To determine if aromatherapy, specifically inhaled essential oil, is beneficial for side effects related to cancer treatments involving chemotherapy, targeted therapy, and/or immunotherapy administered intravenously.
II. To describe the effect of inhaled ginger essential oil, German chamomile essential oil, and bergamot essential oil on nausea and anxiety of patients receiving chemotherapy, targeted therapy, and/or immunotherapy administered intravenously.
III. To describe the effect of decreased levels of nausea and/or anxiety on levels of appetite and/or fatigue.
IV. To evaluate the acceptability of using a personal inhalation bottle for inhalation of essential oils.
OUTLINE: Patients are randomized to 1 of 4 groups.
GROUP I: Patients inhale 7 drops of bergamot essential oil using a personalized inhalation bottle three times daily (TID) (morning, midday, and evening) for up to 7 days. Patients also use a journal to document symptoms, time of inhalation, and medication use TID for up to 7 days.
GROUP II: Patients inhale 7 drops of chamomile essential oil and complete journal as in group I.
GROUP III: Patients inhale 7 drops of ginger essential oil and complete journal as in group I.
GROUP IV (CONTROL): Patients inhale 7 drops of almond essential oil and complete journal as in group I.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
SUPPORTIVE_CARE
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group I (bergamot essential oil)
Patients inhale 7 drops of bergamot essential oil using an essential oil administration bottle TID (morning, midday, and evening) for up to 7 days. Patients also use a journal to document symptoms, time of inhalation, and medication use TID for up to 7 days.
Aromatherapy and Essential Oils
Use bergamot essential oil
Subject Diary
Complete journal
Group II (chamomile essential oil)
Patients inhale 7 drops of chamomile essential oil and complete journal as in group I.
Aromatherapy and Essential Oils
Use chamomile essential oil
Subject Diary
Complete journal
Group III (ginger essential oil)
Patients inhale 7 drops of ginger essential oil and complete journal as in group I.
Aromatherapy and Essential Oils
Use ginger essential oil
Subject Diary
Complete journal
Group IV (almond essential oil)
Patients inhale 7 drops of almond essential oil and complete journal as in group I.
Aromatherapy and Essential Oils
Use almond essential oil
Subject Diary
Complete journal
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Aromatherapy and Essential Oils
Use bergamot essential oil
Aromatherapy and Essential Oils
Use chamomile essential oil
Aromatherapy and Essential Oils
Use ginger essential oil
Aromatherapy and Essential Oils
Use almond essential oil
Subject Diary
Complete journal
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Receiving chemotherapy, targeted therapy, and/or immunotherapy
* Not naive to the treatment
* Must be able to read and write English
Exclusion Criteria
* Asthma diagnosis
* Patients receiving only octreotide injections
* Patients receiving floxuridine (FUDR) via hepatic artery infusion (HAI) pump only
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Ohio State University Comprehensive Cancer Center
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Amber Williams
Principal Investigator
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Amber Williams, MSN, RN, OCN
Role: PRINCIPAL_INVESTIGATOR
Ohio State University Comprehensive Cancer Center
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Countries
Review the countries where the study has at least one active or historical site.
Related Links
Access external resources that provide additional context or updates about the study.
The Jamesline
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
NCI-2019-00340
Identifier Type: REGISTRY
Identifier Source: secondary_id
OSU-18136
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.